Early Efficacy With Mosunetuzumab Appears Promising for Follicular and Other Lymphomas

January 25, 2019
Elizabeth L. Budde, MD, PhD

Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.

Elizabeth L. Budde, MD, PhD, assistant professor in department of hematology at City of Hope, discusses the interim efficacy results from a phase I study of mosunetuzumab in patients with lymphomas.

While this data is still early, Budde says the efficacy results are encouraging. In patients with follicular lymphoma, there was a 69% overall response rate (ORR) and 40% of patients achieved complete response (CR). For diffuse large B-cell lymphoma, the ORR was up to 40% with a 19% CR rate.

In the patients who achieved CR, only 1 relapsed, Budde says. However, the patient received a second treatment and went into a complete remission again. The patients have been followed for close to 300 days, with some of the longest patients closer to 2 years in remission.